All In Biotech

NDA 019992 · Sandoz

Ciloxan

Ciprofloxacin Hydrochloride · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Mar 21, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1990

Dec 31, 1990

Approved uses

2

Original approval plus efficacy supplements

Registered trials

364

90 Phase 3, 32 recruiting

FAERS reports

6,204

5,373 serious, 523 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 5, 2026.

INDICATIONS AND USAGE Ciprofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Corneal Ulcers: Pseudomonas aeruginosa Serratia marcescens* Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus (Viridans Group)* Conjunctivitis: Haemophilus influenzae Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae *Efficacy for this organism was studied in fewer than 10 infections.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 27, 1994 Supplement 4 · Efficacy
  • Dec 31, 1990 Original approval · Type 3 - New Dosage Form Pediatric Medical Review
1 products under this application
  • CILOXAN · CIPROFLOXACIN HYDROCHLORIDE EQ 0.3% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Ciprofloxacin" as an intervention, any sponsor and status, largest first.

All 364 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • vomiting752
  • pneumonia707
  • dyspnoea698
  • off label use668
  • pain654
  • nausea641
  • drug hypersensitivity637
  • malaise592
  • diarrhoea587
  • drug ineffective543
  • fatigue533
  • wheezing522

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200441
200567
200663
200766
200889
2009163
201080
2011119
2012298
201372
201481
2015108
2016132
2017141
2018275
2019501
2020417
2021477
2022603
2023612
2024676
2025679
2026441

Recalls

1 FDA enforcement reports for this application.

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ciloxan (Ciprofloxacin HCl)

2024 spending

$1.5M

Beneficiaries

3,881

5,419 claims

Per beneficiary

$391

$75.76 per unit

View as table
YearSpending
2020$0
2021$445,517
2022$1,277,565
2023$1,460,940
2024$1,517,511

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,835 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.